FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208153007> ?p ?o ?g. }

• W3208153007 abstract "Future Science OAVol. 7, No. 9 EditorialOpen AccessDoes perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?Luca Scafuri, Antonella Sciarra, Felice Crocetto, Matteo Ferro, Carlo Buonerba, Francesco Ugliano, Germano Guerra, Roberto Sanseverino & Giuseppe Di LorenzoLuca ScafuriOncology Unit, Hospital ‘Andrea Tortora,’ ASL Salerno, Pagani, 84016, ItalyAssociazione O.R.A., Somma Vesuviana, Naples, ItalySearch for more papers by this author, Antonella SciarraDepartment of Experimental Medicine, University of Campania ‘Luigi Vanvitelli,’ Naples, NA, 80131, ItalySearch for more papers by this author, Felice CrocettoDepartment of Neurosciences, Reproductive Sciences & Odontostomatology, Federico II University, Naples, 80131, ItalySearch for more papers by this author, Matteo FerroDivision of Urology, European Institute of Oncology (IEO), IRCCS, Milan, 20099, ItalySearch for more papers by this author, Carlo Buonerba*Author for correspondence: E-mail Address: carbuone@hotmail.comOncology Unit, Hospital ‘Andrea Tortora,’ ASL Salerno, Pagani, 84016, ItalyAssociazione O.R.A., Somma Vesuviana, Naples, ItalySearch for more papers by this author, Francesco UglianoDepartment of Medicine & Health Science, University of Molise, Campobasso, 86100, ItalySearch for more papers by this author, Germano GuerraDepartment of Medicine & Health Science, University of Molise, Campobasso, 86100, ItalySearch for more papers by this author, Roberto SanseverinoDepartment of Urology, Umberto I Hospital, ASL Salerno, Nocera Inferiore, 84014, ItalySearch for more papers by this author & Giuseppe Di LorenzoOncology Unit, Hospital ‘Andrea Tortora,’ ASL Salerno, Pagani, 84016, ItalyAssociazione O.R.A., Somma Vesuviana, Naples, ItalyDepartment of Medicine & Health Science, University of Molise, Campobasso, 86100, ItalySearch for more papers by this authorPublished Online:29 Oct 2021https://doi.org/10.2144/fsoa-2021-0092AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: adjuvant therapybladder cancerneoadjuvant therapyAlthough urothelial carcinoma can occur in any part of the urinary tract, 90–95% of urothelial malignancies arise in the bladder [1]. Conversely, approximately 90% of bladder malignancies have a urothelial origin [2]. According to GLOBOCAN, approximately 570,000 individuals were diagnosed with bladder cancer (BCa) in 2020 worldwide, with approximately 210,000 dying of the disease [3]. Southern Europe is the world area presenting with the highest incidence of BCa in males [2], with peaks of over 70 cases per 100,000 males in certain areas of southern Italy [4]. Cystectomy [5] and radical nephroureterectomy [6] represent the mainstay of treatment of localized urothelial cancer that is not amenable to conservative treatment such as intravescical BCG [7]. While both chemotherapy based on platinum agents and immune therapy based on anti PD-1/PDL-1 agents (programmed death-1/programmed death ligand-1) such as pembrolizumab and avelumab have been definitively proven to extend survival in patients with advanced/metastatic disease [8–10], their effect in terms of survival prolongation in the perioperative setting requires to be better investigated. In a meta-analysis [11] assessing overall survival in 2890 BCa patients who received neoadjuvant platinum-based chemotherapy followed by radical cystectomy and 10,418 BCa patients who underwent radical cystectomy alone, neoadjuvant chemotherapy was associated with a 18% reduction of the risk of death with a hazard radio (HR) of 0.82 (95% CI: 0.71–0.95; p = 0.009). Conversely, in the POUT randomized-controlled trial enrolling an overall sample of 261 patients with urothelial carcinoma of the upper urinary tract staged as either pT2-T4 pN0-N3 M0 or pTany N1–3 M0 after nephroureterectomy, adjuvant chemotherapy based on cisplatin/carboplatin plus gemcitabine compared with observation was associated with a significant 55% reduction of the risk of disease recurrence [12]. Although the POUT investigators concluded that either cisplatin or carboplatin may be used in the adjuvant setting, therapy based on cisplatin versus carboplatin was associated with a HR of 0.35 (p < 0.001) versus 0.66 (p = 0.21), respectively, so we believe that evidence from the POUT trial supports the use of cisplatin as opposed to carboplatin whenever cisplatin is feasible. In this regard, we hypothesize that the use of sequential neoadjuvant plus (in select patients) adjuvant platinum-based therapy may be advantageous compared with adjuvant therapy alone in patients with upper tract urothelial carcinoma, as a substantial proportion of patients are expected to become cisplatin-ineligible after nephroureterectomy.Sequential use of neoadjuvant and adjuvant therapy in urothelial carcinoma patients may represent a disease-specific paradigm that may be appliable with success both to chemotherapy and immunotherapy. In this regard, we read with interest the results obtained in one recently published meta-analysis that assessed survival differences in patients with pT3-T4 and/or pN+ muscle-invasive BCa who underwent neoadjuvant chemotherapy + surgery with versus without adjuvant chemotherapy [13]. In the overall sample of 3096 participants, of whom 2355 (76.1%) and 741 (23.9%) did not and did receive adjuvant chemotherapy, respectively, adjuvant chemotherapy was associated with a significant advantage in overall survival (HR: 0.84; 95%CI: 0.75–0.94; p = 0.002) and disease-specific survival (HR: 0.56: 95% CI: 0.32–0.99; p = 0.05). Interestingly, the magnitude of the overall versus disease-specific survival advantage may be more limited, possibly due to the medium-to-long term effects of chemotherapy on noncancer-specific survival, which is consistent with findings obtained by our research group, suggesting a higher noncancer mortality in BCa patients undergoing four versus three cycles of neoadjuvant platinum-based chemotherapy [14]. In this regard, perioperative immunotherapy may be more advantageous compared with chemotherapy in terms of noncancer-specific survival. Results from Phase III Checkmate 274 trial conducted in patients with urothelial cancer who were randomized to 1 year anti-PD-1 agent nivolumab or placebo administered after radical cystectomy or (nephro)-ureterectomy have been published recently [15]. Adjuvant nivolumab compared with placebo for a year was associated with a significant HR for recurrence or death of 0.70 (98% CI: 0.55–0.90; p < 0.001), with median disease-free survival (DFS) of 20.8 versus 10.8 months, respectively. Of note, there was a signal of a potential greater effectiveness of nivolumab in patients who had undergone prior neoadjuvant cisplatin-based chemotherapy (HR for progression = 0.51). This finding is consistent with differences in median DFS reported in the Phase III IMvigor010 trial assessing adjuvant atezolizumab versus observation in urothelial carcinoma patients after radical surgery [16], with a median DFS of 16.8 versus 19.4 months in those who had not received neoadjuvant chemotherapy compared with 19.8 versus 16.5 months in those who had received neoadjuvant chemotherapy. We also note that neoadjuvant immunotherapy based on anti-PD-1 agents prior to cystectomy has yielded exciting results. The updated results obtained in the PURE-01 in 114 BCa patients receiving pembrolizumab prior to cystectomy shoed a pT0 rate of 37% (95% CI: 28–46) and a pT ≤ 1 rate of 55% (95% CI: 46–65) [17].Given the results reviewed here, we hypothesize that the best possibilities of cure in patients with muscle-invasive urothelial cancer are provided by perioperative cisplatin-based chemotherapy + immunotherapy combination. Given medium-to-long term toxicity associated chemotherapy, novel trials may be designed to explore the approach based on delivering a minimum number of cisplatin-based chemotherapy cycles (e.g., three) prior to surgery in combination with immunotherapy and administer immunotherapy only as adjuvant therapy in those who have achieved a complete pathologic response. The perioperative use of pembrolizumab in combination with chemotherapy in cisplatin-eligible muscle-invasive BCa and of pembrolizumab with or without enfortumab vedotin in cisplatin-ineligible muscle-invasive BCa is currently being explored in ongoing Phase III trials [18]. The results of these trials are eagerly awaited and may confirm that the ‘perioperative paradigm’ represents the best therapeutic approach in patients with muscle-invasive urothelial carcinoma undergoing radical surgery.Financial & competing interests disclosureC Buonerba (in the last 3 years) has provided consulting to Ipsen. His Institution has received research funding from Sanofi, Astellas and AstraZeneca. C Buonerba serves as an editorial board member of Future Science OA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1. Milojevic B, Dzamic Z, Kajmakovic B, Milenkovic Petronic D, Sipetic Grujicic S. Urothelial carcinoma: recurrence and risk factors. J. BUON. 20(2), 391–398 (2015).Google Scholar2. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med. Sci. (Basel.) 8(1), 15 (2020).CAS, Google Scholar3. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).Crossref, Google Scholar4. Di Lorenzo G, Federico P, De Placido S, Buonerba C. Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: a systematic review. Crit. Rev. Oncol. Hematol. 96(3), 534–541 (2015).Crossref, Google Scholar5. Bada M, de Concilio B, Crocetto F et al. Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes. Minerva Urol. Nefrol. 72(5), 641–643 (2020).Crossref, Google Scholar6. Veccia A, Antonelli A, Francavilla S et al. Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases. World J. Urol. 38(4), 845–852 (2020).Crossref, Google Scholar7. Ferro M, Di Lorenzo G, Vartolomei MD et al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World J. Urol. 38(1), 143–150 (2020).Crossref, CAS, Google Scholar8. Ferro M, Babă DF, de Cobelli O et al. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Sci. OA 7(7), FSO709 (2021).Link, CAS, Google Scholar9. Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376(11), 1015–1026 (2017).Crossref, CAS, Google Scholar10. Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383(13), 1218–1230 (2020).Crossref, CAS, Google Scholar11. Hamid ARAH, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol. 20(1), 158 (2020).Crossref, CAS, Google Scholar12. Birtle A, Johnson M, Chester J et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a Phase III, open-label, randomised controlled trial. Lancet 395(10232), 1268–1277 (2020).Crossref, CAS, Google Scholar13. Krajewski W, Nowak Ł, Moschini M et al. Impact of adjuvant chemotherapy on survival of patients with advanced residual disease at radical cystectomy following neoadjuvant chemotherapy: systematic review and meta-analysis. J. Clin. Med. 10(4), 651 (2021).Crossref, CAS, Google Scholar14. Ferro M, de Cobelli O, Musi G et al. Three vs. four cycles of neoadjuvant chemotherapy for localized muscle invasive bladder cancer undergoing radical cystectomy: a retrospective multi-institutional analysis. Front. Oncol. 11, 651745 (2021).Crossref, Google Scholar15. Bajorin DF, Witjes JA, Gschwend JE et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384(22), 2102–2114 (2021).Crossref, CAS, Google Scholar16. Bellmunt J, Hussain M, Gschwend JE et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, Phase III trial. Lancet Oncol. 22(4), 525–537 (2021).Crossref, CAS, Google Scholar17. Necchi A, Raggi D, Gallina A et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur. Urol. 77(4), 439–446 (2020).Crossref, CAS, Google Scholar18. Galsky MD, Hoimes CJ, Necchi A et al. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 17(24), S3137–S3150 (2021).Crossref, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 7, No. 9 Follow us on social media for the latest updates Metrics Downloaded 203 times History Received 2 August 2021 Accepted 17 August 2021 Published online 29 October 2021 Published in print October 2021 Information© 2021 Future Science LtdKeywordsadjuvant therapybladder cancerneoadjuvant therapyFinancial & competing interests disclosureC Buonerba (in the last 3 years) has provided consulting to Ipsen. His Institution has received research funding from Sanofi, Astellas and AstraZeneca. C Buonerba serves as an editorial board member of Future Science OA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download" @default.
• W3208153007 created "2021-11-08" @default.
• W3208153007 creator A5014614796 @default.
• W3208153007 creator A5022468686 @default.
• W3208153007 creator A5032741879 @default.
• W3208153007 creator A5035375004 @default.
• W3208153007 creator A5048030769 @default.
• W3208153007 creator A5055464636 @default.
• W3208153007 creator A5077241595 @default.
• W3208153007 creator A5079919373 @default.
• W3208153007 creator A5085376563 @default.
• W3208153007 date "2021-10-01" @default.
• W3208153007 modified "2023-09-27" @default.
• W3208153007 title "Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?" @default.
• W3208153007 cites W1935733038 @default.
• W3208153007 cites W2114430238 @default.
• W3208153007 cites W2588916311 @default.
• W3208153007 cites W2937958445 @default.
• W3208153007 cites W2988581606 @default.
• W3208153007 cites W2990734356 @default.
• W3208153007 cites W3007264925 @default.
• W3208153007 cites W3011714452 @default.
• W3208153007 cites W3035851312 @default.
• W3208153007 cites W3087464965 @default.
• W3208153007 cites W3093100665 @default.
• W3208153007 cites W3127419476 @default.
• W3208153007 cites W3128646645 @default.
• W3208153007 cites W3138703636 @default.
• W3208153007 cites W3153814730 @default.
• W3208153007 cites W3161519348 @default.
• W3208153007 cites W3163417926 @default.
• W3208153007 cites W3163995648 @default.
• W3208153007 doi "https://doi.org/10.2144/fsoa-2021-0092" @default.
• W3208153007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8558855" @default.
• W3208153007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34737893" @default.
• W3208153007 hasPublicationYear "2021" @default.
• W3208153007 type Work @default.
• W3208153007 sameAs 3208153007 @default.
• W3208153007 citedByCount "2" @default.
• W3208153007 countsByYear W32081530072022 @default.
• W3208153007 crossrefType "journal-article" @default.
• W3208153007 hasAuthorship W3208153007A5014614796 @default.
• W3208153007 hasAuthorship W3208153007A5022468686 @default.
• W3208153007 hasAuthorship W3208153007A5032741879 @default.
• W3208153007 hasAuthorship W3208153007A5035375004 @default.
• W3208153007 hasAuthorship W3208153007A5048030769 @default.
• W3208153007 hasAuthorship W3208153007A5055464636 @default.
• W3208153007 hasAuthorship W3208153007A5077241595 @default.
• W3208153007 hasAuthorship W3208153007A5079919373 @default.
• W3208153007 hasAuthorship W3208153007A5085376563 @default.
• W3208153007 hasBestOaLocation W32081530071 @default.
• W3208153007 hasConcept C121608353 @default.
• W3208153007 hasConcept C126322002 @default.
• W3208153007 hasConcept C141071460 @default.
• W3208153007 hasConcept C185926286 @default.
• W3208153007 hasConcept C2777546739 @default.
• W3208153007 hasConcept C2780352672 @default.
• W3208153007 hasConcept C3019882237 @default.
• W3208153007 hasConcept C31174226 @default.
• W3208153007 hasConcept C530470458 @default.
• W3208153007 hasConcept C71924100 @default.
• W3208153007 hasConceptScore W3208153007C121608353 @default.
• W3208153007 hasConceptScore W3208153007C126322002 @default.
• W3208153007 hasConceptScore W3208153007C141071460 @default.
• W3208153007 hasConceptScore W3208153007C185926286 @default.
• W3208153007 hasConceptScore W3208153007C2777546739 @default.
• W3208153007 hasConceptScore W3208153007C2780352672 @default.
• W3208153007 hasConceptScore W3208153007C3019882237 @default.
• W3208153007 hasConceptScore W3208153007C31174226 @default.
• W3208153007 hasConceptScore W3208153007C530470458 @default.
• W3208153007 hasConceptScore W3208153007C71924100 @default.
• W3208153007 hasIssue "9" @default.
• W3208153007 hasLocation W32081530071 @default.
• W3208153007 hasLocation W32081530072 @default.
• W3208153007 hasLocation W32081530073 @default.
• W3208153007 hasLocation W32081530074 @default.
• W3208153007 hasLocation W32081530075 @default.
• W3208153007 hasLocation W32081530076 @default.
• W3208153007 hasOpenAccess W3208153007 @default.
• W3208153007 hasPrimaryLocation W32081530071 @default.
• W3208153007 hasRelatedWork W2327556405 @default.
• W3208153007 hasRelatedWork W2349210304 @default.
• W3208153007 hasRelatedWork W2352247659 @default.
• W3208153007 hasRelatedWork W2354785620 @default.
• W3208153007 hasRelatedWork W2375359181 @default.
• W3208153007 hasRelatedWork W2390010490 @default.
• W3208153007 hasRelatedWork W2586998360 @default.
• W3208153007 hasRelatedWork W2804629518 @default.
• W3208153007 hasRelatedWork W4238974137 @default.
• W3208153007 hasRelatedWork W4324096639 @default.
• W3208153007 hasVolume "7" @default.
• W3208153007 isParatext "false" @default.
• W3208153007 isRetracted "false" @default.
• W3208153007 magId "3208153007" @default.
• W3208153007 workType "article" @default.